🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Krishna Institute of Medical Sciences Limited KIMS NIFTY_SMALLNSEPHARMA

Healthcare · Medical Care Facilities · India
https://www.kimshospitals.com
Company Profile ↓
₹816.55
+14.38% 1Y
Mkt Cap₹32,673.34 Cr
P/E84.97
P/B14.26
52W High₹850.65
52W Low₹582.10
Book Value₹56.17
EPS (TTM)₹9.61

Company Overview

Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand in India. The company offers arthroscopy and shoulder, cardiology, cardiothoracic and cardiovascular, organ transplant, medical and surgical gastroenterology, hepatology, orthopaedic, neurology, neurosurgery, nephrology, urology, oncology, pediatric, neonatology, obstetrics and gynaecology, fertility, dental science, emergency and critical care, vascular, rehabilitation and physiotherapy services. It also provides pulmonology, diagnostic and imaging, ophthalmology, ENT, rheumatology and clinical immunology, internal medicine, interventional radiology, diabetology, endocrinology, general surgery, infectious disease, dermatology, thoracic surgery, psychiatry, plastic and reconstructive surgery, transfusion medicine, clinical psychology, anesthesiology, and tele medicine services. In addition, the company operates clinical immunology allergy, bone marrow transplantation, hair transplant, andrology, fertility, alzheimer, arthroscopy, bone and joint, breast, dialysis, female urology, IUI, IVF, joint replacement, kidney health and transplant, ICU, spine, stroke, TAVR/TAVI, hepatobiliary surgery, and trauma centers, as well as pain and wellness clinics. Further, it provides bariatric, thoracic, oral maxillofacial, and endovascular surgery services. Krishna Institute of Medical Sciences Limited was incorporated in 1973 and is based in Secunderabad, India.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 21.7% CAGR over the past five years.

Recent Developments

  • Mar 2026 Revenue of ₹3,904.60 Cr (+28.7% YoY); net profit ₹241.40 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +28.6%, earnings -37.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 21.7%, profit CAGR -10.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:21.67%
1 Year:28.65%

Compounded Profit Growth

5 Years:-10.46%
1 Year:-37.22%

Stock Price Performance

1 Year:+14.38%
6 Months:+31.67%
3 Months:+22.76%
1 Month:+6.07%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 87% of range
₹582.10 ₹850.65
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)55.72 · Neutral
Price Performance
1M+6.07%
3M+22.76%
6M+31.67%
1Y+14.38%
Valuation vs Sector

P/E of 84.97 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 21.7% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 85.0.
  • Earnings shrank at -10.5% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
84.97
Industry PE
39.97
Forward P/E
47.80
PEG Ratio
-
Book Value
₹56.17
Price to Book
14.26
P/S
8.21
EV/EBITDA
48.38
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
21.67%
Profit 5Y
-10.46%
Revenue (YoY)
28.65%
Earnings (YoY)
-37.22%

Profitability & Returns

ROCE
8.23%
ROE
10.74%
ROA
3.11%
Profit Margin
6.18%
Op Margin
13.29%
Gross Margin
61.82%
EPS (Latest Qtr)
₹1.06
EPS (TTM)
₹9.61

Balance Sheet & Liquidity

Debt/Equity
1.89
Quick Ratio
0.68
Current Ratio
0.76
Debt
₹4,252.90 Cr
Total Assets
₹7,758.70 Cr
Current Assets
₹937.40 Cr
Working Capital
₹-301.50 Cr

Ownership

Promoter Holding
41.73%
Chg in Prom Hold
-2.07%
FII / Inst Holding
38.31%
Chg in FII Hold
0.03%

Financial Snapshot

Enterprise Value
₹32,673.34 Cr
Total Revenue (TTM)
₹3,904.60 Cr
EBITDA
₹819.60 Cr
Free Cash Flow
₹-917.10 Cr
Operating Cash Flow
₹510.80 Cr
Shares Outstanding
₹40.01 Cr
Gross Margin
61.82%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 KIMS Krishna Institute of Medical Sciences Limited NIFTY_SMALLNSEPHARMA 816.55 84.97 ₹32,673.34 Cr 0.00% 8.23% 10.74% 21.67% -10.46%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 576.00 Cr606.00 Cr652.00 Cr606.00 Cr634.00 Cr688.00 Cr777.00 Cr772.00 Cr796.90 Cr871.60 Cr960.70 Cr997.70 Cr1,074.60 Cr
Cost of Revenue --------301.20 Cr335.00 Cr195.20 Cr196.90 Cr412.70 Cr
Gross Profit --------495.70 Cr536.60 Cr765.50 Cr800.80 Cr661.90 Cr
Operating Expenses 413.00 Cr449.00 Cr475.00 Cr459.00 Cr475.00 Cr509.00 Cr559.00 Cr585.00 Cr350.30 Cr397.40 Cr627.60 Cr680.60 Cr540.40 Cr
Operating Income 128.00 Cr125.00 Cr144.00 Cr112.00 Cr113.00 Cr140.00 Cr177.00 Cr142.00 Cr145.40 Cr139.20 Cr137.90 Cr120.20 Cr121.50 Cr
EBITDA 163.00 Cr157.00 Cr177.00 Cr147.00 Cr159.00 Cr179.00 Cr218.00 Cr187.00 Cr213.30 Cr199.70 Cr207.90 Cr204.10 Cr207.90 Cr
Interest Expense 5.00 Cr9.00 Cr9.00 Cr12.00 Cr16.00 Cr18.00 Cr20.00 Cr26.00 Cr26.70 Cr32.60 Cr45.00 Cr56.80 Cr68.10 Cr
Pretax Income 127.00 Cr119.00 Cr139.00 Cr102.00 Cr100.00 Cr127.00 Cr162.00 Cr135.00 Cr134.00 Cr113.70 Cr96.80 Cr68.60 Cr54.80 Cr
Tax Provision 27.94 Cr32.13 Cr37.53 Cr25.50 Cr28.00 Cr31.75 Cr42.12 Cr41.85 Cr27.90 Cr28.70 Cr24.80 Cr16.70 Cr21.70 Cr
Net Income 99.00 Cr87.00 Cr101.00 Cr77.00 Cr72.00 Cr95.00 Cr121.00 Cr92.00 Cr101.80 Cr78.60 Cr66.90 Cr53.40 Cr42.50 Cr
Diluted EPS 2.332.022.301.801.642.162.682.222.541.961.671.331.06

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 512.00 Cr567.00 Cr664.00 Cr918.00 Cr1,123.00 Cr1,330.00 Cr-2,167.66 Cr2,474.00 Cr3,035.00 Cr3,904.60 Cr
Cost of Revenue -------827.08 Cr952.80 Cr1,126.40 Cr1,490.60 Cr
Gross Profit -------1,340.58 Cr1,521.20 Cr1,908.60 Cr2,414.00 Cr
Operating Expenses 403.00 Cr450.00 Cr593.00 Cr833.00 Cr872.00 Cr953.00 Cr-851.11 Cr1,018.70 Cr1,303.00 Cr1,895.20 Cr
Operating Income 73.00 Cr83.00 Cr31.00 Cr29.00 Cr180.00 Cr307.00 Cr-489.47 Cr502.50 Cr605.60 Cr518.80 Cr
EBITDA 109.00 Cr118.00 Cr71.00 Cr85.00 Cr251.00 Cr377.00 Cr-643.49 Cr652.40 Cr825.60 Cr819.60 Cr
Interest Expense 37.00 Cr32.00 Cr88.00 Cr49.00 Cr44.00 Cr37.00 Cr-29.32 Cr46.40 Cr90.30 Cr202.50 Cr
Pretax Income 41.00 Cr53.00 Cr-20.00 Cr-15.00 Cr141.00 Cr279.00 Cr-484.91 Cr459.50 Cr558.10 Cr333.90 Cr
Tax Provision 13.12 Cr19.61 Cr-25.20 Cr-33.45 Cr25.38 Cr72.54 Cr-119.09 Cr123.60 Cr143.30 Cr91.90 Cr
Net Income 28.00 Cr33.00 Cr-46.00 Cr-49.00 Cr115.00 Cr205.00 Cr-336.32 Cr310.00 Cr384.50 Cr241.40 Cr
Diluted EPS 0.760.91-1.32-1.283.205.198.388.417.759.61-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 665.00 Cr774.00 Cr954.00 Cr1,114.00 Cr1,194.00 Cr1,433.00 Cr-2,941.30 Cr3,851.70 Cr5,736.00 Cr7,758.70 Cr
Current Assets -------477.64 Cr547.30 Cr697.30 Cr937.40 Cr
Cash & Equivalents -------61.61 Cr46.90 Cr56.00 Cr55.40 Cr
Inventory -------42.87 Cr49.40 Cr64.00 Cr96.90 Cr
Receivables -------252.65 Cr294.40 Cr395.40 Cr554.20 Cr
Total Liabilities -------1,003.34 Cr1,758.60 Cr3,317.20 Cr5,200.20 Cr
Current Liabilities -------296.47 Cr451.90 Cr836.20 Cr1,238.90 Cr
Long Term Debt -------497.44 Cr927.70 Cr1,654.10 Cr2,672.60 Cr
Total Debt 256.00 Cr280.00 Cr753.00 Cr336.00 Cr369.00 Cr316.00 Cr-678.17 Cr1,355.50 Cr2,556.70 Cr4,252.90 Cr
Total Equity 263.00 Cr327.00 Cr-159.00 Cr540.00 Cr598.00 Cr864.00 Cr-1,669.54 Cr1,828.20 Cr2,137.80 Cr2,247.40 Cr
Shares Outstanding -------40.01 Cr40.01 Cr40.01 Cr40.01 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 95.00 Cr82.00 Cr106.00 Cr134.00 Cr202.00 Cr356.00 Cr-432.09 Cr521.20 Cr581.80 Cr510.80 Cr
Investing Cash Flow -41.00 Cr-100.00 Cr-64.00 Cr-110.00 Cr-125.00 Cr-354.00 Cr--546.89 Cr-752.60 Cr-1,116.20 Cr-1,451.70 Cr
Financing Cash Flow -65.00 Cr24.00 Cr-39.00 Cr-27.00 Cr-44.00 Cr10.00 Cr-19.64 Cr216.70 Cr543.10 Cr940.30 Cr
Capital Expenditure -34.00 Cr-100.00 Cr-57.00 Cr-77.00 Cr-52.00 Cr-94.00 Cr--574.52 Cr-647.30 Cr-1,008.90 Cr-1,427.90 Cr
Free Cash Flow 61.00 Cr-18.00 Cr49.00 Cr57.00 Cr150.00 Cr262.00 Cr--142.44 Cr-126.10 Cr-427.10 Cr-917.10 Cr
Net Change in Cash -11.00 Cr5.00 Cr3.00 Cr-3.00 Cr32.00 Cr12.00 Cr--95.17 Cr-14.70 Cr8.70 Cr-60.00 L

Ratios (Annual)

Figures in %.

Metric Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -------61.8%61.5%62.9%61.8%
Operating Margin % 14.3%14.6%4.7%3.2%16.0%23.1%-22.6%20.3%20.0%13.3%
Net Margin % 5.5%5.8%-6.9%-5.3%10.2%15.4%-15.5%12.5%12.7%6.2%
ROE % 10.6%10.1%28.9%-9.1%19.2%23.7%-20.1%17.0%18.0%10.7%
ROCE % -------18.5%14.8%12.4%8.0%

Shareholding Pattern

Insiders
41.73%
Institutions
38.31%
Public Float
65.75%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for KIMS

Google News hu, 25 Jun 2026

KIMS Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTFA4OU5zcjRJcXJUbG9UMWpXLTZLX3FmZk5BSnlLSFdqelZ3TURSMWVnenZjTWJkSWZiaTRmd1U0ZU5tQnNTMGM1Q3RKS3RUNEs4ekt0eU9pQXVQaHliRV9ydkxZajBXSnNPbGZkUGxQTkJFZS1oUWc?oc=5" target="_blank">KIMS For…

Google News Sun, 12 Jul 2026

Yoon Faces Verdict on Poll Case as Court Rules on Kim's Stock Case - Seoul Economic Daily

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNVGQyU3ZPVXhvVjV2MGlBNE5EWWdhVmJyN1VNOW5zQkQ1dm9vZlRidy13OWIyZDItVDE1S1QtOXBZMTFEQXlSckNtR19qcWhlR25INnUwZHBEQ0Nja3ctdmlEQ2ZLZjMxLXZ2Uk53dm5BTERQWDRvOV9TSVZCTjRmYnFaR0liaW1SY1RsME…

Google News ue, 14 Jul 2026

KIMS approves preferential warrant issue in EGM - scanx.trade

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQYjMxSVhRYWt1STdXY1ltb1ROZzg1Q1dlZG41dUdrRmo5ZnlYZ1hBVmJTRGxuT0ZBV2s3YmYxaWgtemhuX3FZRU9ZcldjR0wwNVZNUEpFYmZNb0ppd3hNOUVyS3p4NFJvaVZhd3ZWLVhKVVJmcTJ2dWpSVjZjcU1YUEFJcHNGWi1ncW15SG…

Google News Sun, 05 Jul 2026

KIMS Issues Corrigendum to EGM Notice on Preferential Share Issue - The Globe and Mail

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxOaWJtbVphMkd3NTZ2cTlCRmJqb0E2U1BaNkR3OEc5TDZxYi05NE0ycEI0U0QwZmREbVJfaFBTSUg0YjFfeWJ5ZjduTWRjeTh6NEd6N2FsUDA3NXVaY3N2Zm1fQWd6d1hlNUkyMFBhVEZPc2RlOU4tN1FXZldfd3FtY25NSzJEMk5NeHEybF…

Google News hu, 22 Jan 2026

Should Weakness in Krishna Institute of Medical Sciences Limited's (NSE:KIMS) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxPYUcwWG5sdWEyWWpsZFVHcmNycW04R1ltWG5vbWNXUW9GMzJrdFdLRkRraGR6dk1EZkM5QzdVZFZYbElpa3UzbFBYMEwyVG1heGw0RWJJdllYYUhKYmpUem93S1VRaFlwd0pzMHhOTXZhNFBmZEgxS1A2ZGVKMWFLQ2l3cXVNeVdqUjFGa1…

Google News Wed, 13 May 2026

Stock Radar: KIMS breaks out from symmetrical triangle pattern; where is the stock headed? - The Economic Times

<a href="https://news.google.com/rss/articles/CBMi8wFBVV95cUxOcEJSWWEyNkFiTV9ZdVpGQ3NGb1A5eUlCY05QOFRCRGhtcElKUWctUVQ0aVZEM2NrU0ZrU2FhUXRpWGp4UEpHb0MyVmRoQkhwdjVNNVYzQ0hKMnR2cjV3TXFsbFBZZ2MzbUphRVFscm9JTjk4eVJ5VXRqM21aS2dCRFZmLTRncjhJY25ldE…

KIMS — Frequently Asked Questions

What is the current share price of Krishna Institute of Medical Sciences Limited (KIMS)?

As of 2026-07-15 09:52 IST, Krishna Institute of Medical Sciences Limited (KIMS) trades at ₹816.55 on NSE. Its 52-week range is ₹582.10 to ₹850.65.

What is the market capitalisation of KIMS?

Krishna Institute of Medical Sciences Limited (KIMS) has a market capitalisation of ₹32,673.34 Cr on NSE.

What is the P/E ratio of KIMS?

KIMS trades at a trailing price-to-earnings (P/E) ratio of 84.97. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 14.26.

What is the return on equity (ROE) of KIMS?

KIMS has a return on equity (ROE) of 10.74%. Its return on capital employed (ROCE) is 8.23%.

Is KIMS a good stock to buy?

This page provides a data-driven analysis of Krishna Institute of Medical Sciences Limited (KIMS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space